+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and clinical studies of piperacillin

Laboratory and clinical studies of piperacillin

Chinese Medical Journal 96(12): 885-892

Antibacterial activity, clinical pharmacology and clinical trials of piperacillin are reported. Bacterial susceptibility testing of 387 clinical isolates revealed that piperacillin is active against various gram-positive and gram-negative organisms, with especially marked activity against gram-negative organisms; inhibition rates against Pseudomonas aeruginosa and Escherichia coli were 90 and 79%, respectively. Peak serum levels after i.m. and i.v. injections and i.v. drip of 1 gm piperacillin in normal volunteers were 25, 142.1 and 58 .mu.g/ml, respectively. Pharmacokinetic parameters were calculated, based upon the specific therapeutic regimens used in treating various infections. Piperacillin was used in 148 infections including peritonitis, lung infections, septicemias, etc.; the total effective rate was 77.7% and the cure rate 55.4%. Adverse reactions were rare; no renal, hepatic or hemopoietic toxicity was noted.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 005787331

Download citation: RISBibTeXText

PMID: 6426881

Related references

Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics. Japanese Journal of Antibiotics 51(6): 395-406, 1998

Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong. International Journal of Antimicrobial Agents 40(3): 280-281, 2012

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. Journal of ChemoTherapy 2(5): 295-299, 1990

Pharmacokinetic studies on the concomitant administration of piperacillin and cefazolin, and piperacillin and cefoperazone in rabbits. Journal of Antibiotics 39(5): 699-712, 1986

Piperacillin-sulbactam versus piperacillin-tazobactam: a multicentre, randomised, single-blind, controlled clinical trial. International Journal of Antimicrobial Agents 26(1): 22-27, 2005

In vitro pharmacodynamics of piperacillin , ciprofloxacin , and piperacillin-tazobactam in single agent and combination studies. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 117, 1994

Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 79(9): 637-643, 2005

A single-blind randomized clinical trial of piperacillin-sulbactam versus piperacillin-tazobactam in the treatment of acute bacterial infections. Zhongguo Kangshengsu Zazhi 30(4): 222-225,232, 2005

Medical treatment of pelvic inflammatory disease. A clinical study on the therapeutic effectiveness of piperacillin + erythromycin and of piperacillin + clindamycin + gentamycin. La Clinica Terapeutica 132(1): 41-44, 1990

Studies on tissue concentrations of cefoperazone and piperacillin classified by the site of the wall of gallbladder and concentration of piperacillin in the bile after operation. Japanese Journal of Antibiotics 37(6): 966-972, 1984

Medical management of inflammatory disease of the pelvis a clinical study of the therapeutic efficacy of piperacillin erythromycin and piperacillin clindamycin gentamicin combinations. Clinica Terapeutica 132(1): 41-44, 1990

Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Journal of Clinical Microbiology 41(7): 3339-3343, 2003

Piperacillin: microbiological and clinical studies. Minerva Medica 74(28-29): 1765-1770, 1983

Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clinical Microbiology and Infection 9(11): 1128-1132, 2003

Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa. ChemoTherapy 50(1): 27-30, 2004